Exhibit 99.1 Paragon 28 Appoints Chadi Chahine as Chief Financial Officer and Executive Vice-President of Supply Chain Operations, Reports Second Quarter 2024 Financial Results and Narrows 2024 Net Revenue Guidance ENGLEWOOD, CO., August 8, 2024 -- Paragon 28, Inc. (NYSE: FNA) ("Paragon 28" or "Company"), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced that Chadi Chahine has been appointed Chief Financial Officer and Executive Vice-President of S ...

SAN FRANCISCO, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Paragon 28, Inc. (NYSE: FNA) investors who suffered substantial losses to submit your losses now. The firm also encourages persons with knowledge who may be able to assist in the investigation to contact its attorneys. Visit: www.hbsslaw.com/investor-fraud/FNA Contact the Firm Now: FNA@hbsslaw.com 844-916-0895 Paragon 28, Inc. (FNA) Investigation: Medical device company Paragon 28 is facing mounting scrutiny over its financial reporting pr ...

NEW YORK, Aug. 04, 2024 (GLOBE NEWSWIRE) -- Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Paragon 28, Inc. (NYSE: FNA) resulting from allegations that Paragon 28 may have issued materially misleading business information to the investing public. So what: If you purchased Paragon 28 securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangem ...

SAN FRANCISCO, Aug. 02, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Paragon 28, Inc. (NYSE: FNA) investors who suffered substantial losses to submit your losses now. The firm also encourages persons with knowledge who may be able to assist in the investigation to contact its attorneys. Visit: www.hbsslaw.com/investor-fraud/FNA Contact the Firm Now: FNA@hbsslaw.com | 844-916-0895 Paragon 28, Inc. (FNA) Investigation: Medical device company Paragon 28 is facing mounting scrutiny over its financial reporting ...

LOS ANGELES, Aug. 1, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Paragon 28, Inc. ("Paragon 28" or "the Company") (NYSE: FNA) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Paragon filed an 8-K with the SEC on July 30, 2024. The filing stated, "On July 3 ...

NEW YORK, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Paragon 28, Inc. ("Paragon 28" or "the Company") (NYSE: FNA). Investors who purchased Paragon 28 securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/FNA. Investigation Details On July 30, 2024, Paragon 28 filed a current report on Form 8-K with the SEC, and stated that "On ...

Paragon 28, Inc. (NYSE:FNA) Q1 2024 Earnings Conference Call May 8, 2024 4:30 PM ET Company Participants Matthew Brinckman - Senior Vice President, Strategy and IR Albert DaCosta - Chairman, CEO, Co Founder Krissy Wright - Interim Chief Financial Officer Conference Call Participants Matthew O'Brien - Piper Sandler & Co. George Sellers - Stephens Inc. Craig Bijou - BofA Securities Mike Matson - Needham & Company, LLC Justin Lin - William Blair & Company LLC Dave Turkaly - Citizens Financial Group Caitlin Cro ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40902 Paragon 28, Inc. (Exact name of registrant as specified in its charter) Delaware 27-3170186 (State or other jurisdiction of ...

Exhibit 99.1 Paragon 28 Reports First Quarter 2024 Financial Results and Reaffirms 2024 Net Revenue Guidance ENGLEWOOD, CO., May 8, 2024 — Paragon 28, Inc. (NYSE: FNA) ("Paragon 28" or "Company"), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today reported financial results for the quarter ended March 31, 2024, and reaffirmed its 2024 net revenue guidance. First Quarter 2024 Financial Results "We are off to a strong start in 2024 and continue to see increased ...

OXFORD, United Kingdom, April 04, 2024 (GLOBE NEWSWIRE) -- OrganOx, a medical device company which is changing the paradigm in liver transplantation in the US and Europe with its groundbreaking normothermic machine perfusion technology, today announces that Stephen (Steve) M. Deitsch will be joining OrganOx as Chief Financial Officer ("CFO") on April 8, 2024. Steve joins OrganOx from Paragon 28 (NYSE:FNA), a leading medical device company exclusively focused on the foot and ankle orthopaedic market, where h ...